JP2021520381A5 - - Google Patents

Info

Publication number
JP2021520381A5
JP2021520381A5 JP2020554286A JP2020554286A JP2021520381A5 JP 2021520381 A5 JP2021520381 A5 JP 2021520381A5 JP 2020554286 A JP2020554286 A JP 2020554286A JP 2020554286 A JP2020554286 A JP 2020554286A JP 2021520381 A5 JP2021520381 A5 JP 2021520381A5
Authority
JP
Japan
Prior art keywords
phenyl
trifluoromethoxy
fluoro
acetamide
piperidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520381A (ja
JP7346441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052731 external-priority patent/WO2019193516A2/en
Publication of JP2021520381A publication Critical patent/JP2021520381A/ja
Publication of JP2021520381A5 publication Critical patent/JP2021520381A5/ja
Application granted granted Critical
Publication of JP7346441B2 publication Critical patent/JP7346441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554286A 2018-04-04 2019-04-03 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用 Active JP7346441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652458P 2018-04-04 2018-04-04
US62/652,458 2018-04-04
PCT/IB2019/052731 WO2019193516A2 (en) 2018-04-04 2019-04-03 Substituted pyridine and pyrimidines and their use as glun2b receptor modulators

Publications (3)

Publication Number Publication Date
JP2021520381A JP2021520381A (ja) 2021-08-19
JP2021520381A5 true JP2021520381A5 (https=) 2022-04-06
JP7346441B2 JP7346441B2 (ja) 2023-09-19

Family

ID=68097960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554286A Active JP7346441B2 (ja) 2018-04-04 2019-04-03 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用

Country Status (5)

Country Link
US (2) US11008302B2 (https=)
EP (1) EP3774732A4 (https=)
JP (1) JP7346441B2 (https=)
MA (1) MA52244A (https=)
WO (1) WO2019193516A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
WO2023083330A1 (zh) * 2021-11-12 2023-05-19 百极优棠(广东)医药科技有限公司 Drak2抑制剂及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
DE69730980T2 (de) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
JP2001139561A (ja) * 1999-11-17 2001-05-22 Dainippon Pharmaceut Co Ltd 5−ハロゲノ−6−(4−トリフルオロメチルフェニル)−4−アミノピリミジン誘導体
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
DE60316542T2 (de) 2002-03-28 2008-07-03 Eisai R&D Management Co., Ltd. 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2006127575A (ru) 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
CA2581454A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2006078992A2 (en) * 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
WO2007115231A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
JPWO2009028543A1 (ja) 2007-08-30 2010-12-02 武田薬品工業株式会社 置換ピラゾール誘導体
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
MX2010009649A (es) 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US8906914B2 (en) * 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
MX2014001088A (es) * 2011-07-28 2015-03-19 Chdi Foundation Inc Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
AU2016291158B2 (en) 2015-07-09 2020-04-30 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途

Similar Documents

Publication Publication Date Title
JP2021520381A5 (https=)
JP2022536773A5 (https=)
HRP20230388T1 (hr) Inhibitori oksazin monoacilglicerol lipaze (magl)
JP2022520811A5 (https=)
ES2569528T3 (es) 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
JP6411895B2 (ja) 治療活性化合物およびその使用方法
FI3883936T3 (fi) Uusia heterosyklisiä yhdisteitä
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
JP2021515033A5 (https=)
JP2023506642A5 (https=)
JP2022546029A5 (https=)
JP2017525757A5 (https=)
JP2019530695A5 (https=)
JP2022534303A5 (https=)
RU2017104264A (ru) 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные
HRP20241201T1 (hr) Novi heterociklički spojevi kao inhibitori monoacilglicerol lipaze
JP2018534326A5 (https=)
JP2019505541A5 (https=)
JP2019508467A5 (https=)
ME02856B (me) Aminopirimidinilni spojevi kao inhibitori jak
US10376510B2 (en) 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
JP2022552655A5 (https=)
JP2017510555A5 (https=)
UA122387C2 (uk) Терапевтично активні сполуки та способи їх застосування
JP2013512899A5 (https=)